DOI QR코드

DOI QR Code

Association of IGFBP-6 Expression with Metabolic Syndrome and Adiponectin and IGF-IR Receptor Levels in Colorectal Cancer

  • Yunusova, Natalia V (Tomsk Cancer Research Institute) ;
  • Spirina, Liudmila V (Tomsk Cancer Research Institute) ;
  • Frolova, Alena E (Tomsk Cancer Research Institute) ;
  • Afanas'ev, Sergey G (Tomsk Cancer Research Institute) ;
  • Kolegova, Elena S (Tomsk Cancer Research Institute) ;
  • Kondakova, Irina V (Tomsk Cancer Research Institute)
  • Published : 2016.08.01

Abstract

Purpose:To assess IGFBP-6 expression in relation with the presence of the metabolic syndrome, adiponectin receptors (AdipoR1 and AdipoR2) and IGF-IR levels in colorectal adenocarcinoma cases. Materials and Methods: IGFBP-6 mRNA and protein levels were analyzed using real-time quantitative PCR and Western blotting in 46 patients. ELISA and flow cytometry were used for evaluation of AdipoR1, AdipoR2 and IGF-IR. Results: The results showed that IGFBP-6 mRNA expression and the IGFBP-6 content were higher in tumor tissue samples of colorectal cancer patients with tahtn without metabolic syndrome. In addition, the IGFBP-6 mRNA expression was associated with tumor invasion (tumor size) and the IGFBP-6 protein level was associated with nodal status. Positive correlations and positive nonlinear relations were found between the IGFBP-6 level and the AdipoR1 and AdipoR2 contents in colorectal cancer patients. Conclusions: The IGFBP-6 mRNA level and protein level were found to be associated with presence of metabolic syndrome. Positive correlations indicated probable cross-talk between the IGF-IR-mediated and adiponectin-mediated signaling pathways in colorectal carcinomas. IGFBP-6 may be considered as a potential biomarker associated with lymphogenous metastasis and the metabolic syndrome in colorectal cancer.

Keywords

Colorectal cancer;insulin-like growth factor binding protein;metabolic syndrome;AdipoR;IGF-IR

Acknowledgement

Supported by : Russian Foundation for Basic Research

References

  1. Ahmad W, Shabbiri K, Ijaz B, et al (2011). Serine 204 phosphorylation and O-${\beta}$-GlcNAC interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma. Virol J, 8, 208. https://doi.org/10.1186/1743-422X-8-208
  2. Ayyildiz T, Dolar E, Ugras N, et al (2014). Association of adiponectin receptor (Adipo-R1/-R2) expression and colorectal cancer. Asian Pac J Cancer Prev, 15, 9385-90. https://doi.org/10.7314/APJCP.2014.15.21.9385
  3. Bach LA, Fu P, Yang Z (2013). Insulin-like growth factor-binding protein-6 and cancer. Clin Sci (Lond), 124, 215-29. https://doi.org/10.1042/CS20120343
  4. Bach LA (2015). Recent insight into the action of IGFBP-6. J Cell Commun Signal, 9, 189-200. https://doi.org/10.1007/s12079-015-0288-4
  5. Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54. https://doi.org/10.1210/er.2001-0033
  6. Ivanova EV, Kondakova IV, Spirina LV, et al (2014). Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. Bulletin Experimental Biol Med, 157, 781-4. https://doi.org/10.1007/s10517-014-2666-y
  7. Kim EJ, Schaffer BS, Kang YH, et al (2002). Decreased production of insulin-like growth factor-binding protein (IGFBP)-6 by transfection of colon cancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of cell proliferation. J Gastroenterol Hepatol, 17, 563-70. https://doi.org/10.1046/j.1440-1746.2002.02703.x
  8. Leng SL, Leeding KS, Whitehead RH, et al (2001). Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-IIinduced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol, 174, 121-7. https://doi.org/10.1016/S0303-7207(00)00444-5
  9. Marinaro JA, Neumann GM, Russo VC, et al (2000). O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur J Biochem, 267, 5378-86. https://doi.org/10.1046/j.1432-1327.2000.01575.x
  10. Mauro L, Pellegrino M, De Amicis F, et al (2014). Evidence that estrogen receptor ${\alpha}$ interferes with adiponectin effects on breast cancer cell growth. Cell Cycle, 13, 553-64. https://doi.org/10.4161/cc.27455
  11. Mauro L, Naimo GD, Riccio E, et al (2015). Cross-talk between adiponectin and IGF-RI in breast cancer. Frontiers Oncol, 5, 1-8.
  12. Minniti CP, Luan D, O'Grady C, et al (1995). Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ, 6, 263-9.
  13. Ogunwobi O, Beales IL (2007). The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3kinase/Akt. Int J Colorectal Dis, 22, 401-9. https://doi.org/10.1007/s00384-006-0181-y
  14. Pennisi PA, Barr V, Nunez NP, et al (2002). Reduced expression of insuline-like growth factor I receptors in MCF breast cancer cells leads to a more metastatic phenotype. Cancer Res, 62, 6529-37.
  15. Resch A, Langer C (2013). Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol, 19, 8515-26. https://doi.org/10.3748/wjg.v19.i46.8515
  16. Samani AA, Yakar S, LeRoith D, et al (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insight. Endocrine Reviews, 28, 20-47. https://doi.org/10.1210/er.2006-0001
  17. Spirina LV, Bochkareva NV, Kondakova IV, et al (2012). Regulation of insulin-like growth NF-${\kappa}B$ proteasome system in endometrial cancer. Molecular Biol, 46, 407-13. https://doi.org/10.1134/S0026893312020173
  18. Spirina LV, Yunusova NV, Kondakova IV, et al (2012). Association of growth factors, HIF-1 and NF-${\kappa}B$ expression with proteasome in endometrial cancer. Mol Biol Rep, 39, 8655-62. https://doi.org/10.1007/s11033-012-1720-y
  19. Sugiyama M, Takahashi H, Hosono K, et al (2009). Adiponectin inhibits colorectal cancer cell growth through the AMPK/ mTOR pathway. Int J Oncol, 34(2), 339-44.
  20. Tae CH, Kim SE, Jung SA, et al (2014). Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC Cancer, 14, 811. https://doi.org/10.1186/1471-2407-14-811
  21. Yunusova NV, Spirina LV, Kondakova IV, et al (2013). The relationship of metalloproteinase PAPP-A expression with the expression of growth and transcriptional factors in endometrial cancer. Biology Bulletin, 40, 253-59. https://doi.org/10.1134/S1062359013030114
  22. Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). The insulin-like growth factors system in ovarian cancer metastasis: the relation with p45 Ser ${\beta}$-catenin. Molekulyrnaya Meditsina, 4, 17-22. [in Russian].
  23. Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). Serum adipokines and their receptors in endometrial and colon cancer patients: relationship with tumor invasion and metastasis. Vopr Onkol, 61, 619-23.
  24. Zhou JR, Blac${\kappa}B$urn GL, Walker WA (2007). Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr, 86, 817-9. https://doi.org/10.1093/ajcn/86.3.817S